News Room
Celebrating 20 Years of Technophage
Twenty years ago, Technophage started as a small startup at the Institute of Molecular Medicine, with a small adventurous team isolating...
TECHNOPHAGE and PHAXIAM Therapeutics Enter Strategic Collaboration on Individualized Phages Therapies Against Bacteria Responsible For ~70% of the Most Common Severe Resistant Infections
TECHNOPHAGE, a Portuguese company specializing in GMP phage development and PHAXIAM Therapeutics, a biopharmaceutical company developing innovative...
Fostering Collaboration: Technophage Joins REVERSE 2 Investigator Meeting in Hyderabad to Advance TP-102 Development
We are delighted to share that Technophage’s Clinical Trial Director, Margarida Barreto, participated in the REVERSE 2 / TP-102_102 Investigator...
Pipeline
Invest in our products
GMP manufacturing
Learn more about GMP manufacturing
Technophage
Who we are, What we do
Therapeutic
areas
TechnoPhage is committed to the development of biological and chemical products for infection, neurosciences and ophthalmology